Objective: Stroke is a frequent complication occurring early and late after surgical aortic valve replacement. There is an unmet clinical need for simple tools to assess postoperative stroke risk. We sought to assess the predictive performance of Congestive heart failure; Hypertension; Age !75 (doubled); Diabetes mellitus; prior Stroke, transient ischemic attack or thromboembolism (doubled); Vascular disease; Age 65 to 74; Sex category (female) (CHA 2 DS 2 -VASc) score in patients undergoing surgical aortic valve replacement with a bioprosthesis.
Incidence rate of stroke/TIA per 100 patient years according to CHA 2 DS 2 -VASc scores.
Central Message
CHA 2 DS 2 -VASc is a valuable tool to identify patients for whom alternative strategies for prevention of late neurologic complications such as left atrial appendage occlusion should be considered.
Perspective
There is an unmet clinical need to identify patients at high risk for stroke and clinically significant bleeds occurring late after SAVR. These high-risk patients may benefit from approaches aimed at reducing the risk of stroke such as long-term oral anticoagulation therapy or surgical occlusion of the left atrial appendage. Therefore, measures to assess these risks would be useful.
See Commentary on page 905.
Stroke and transient ischemic attack (TIA) are common complications after surgical aortic valve replacement (SAVR) with a bioprosthesis both in the short and long term. [1] [2] [3] [4] Because of increased mortality and disability as well as incremental treatment costs related to strokes, there is an unmet clinical need to identify patients at high risk for such neurologic complications after SAVR. Indeed, these high-risk patients may benefit from approaches aimed at reducing the risk of stroke such as long-term oral anticoagulation therapy. 5 Nevertheless, oral anticoagulation therapy is itself associated with an increased risk of severe bleeding events, and thus, some patients might be candidates for closure of the left atrial appendage. Therefore, measures to assess the risk and benefit of currently available treatment options would be useful.
The Congestive heart failure; Hypertension; Age ! 75 (doubled); Diabetes mellitus; prior Stroke, transient ischemic attack or thromboembolism (doubled); Vascular disease; Age 65 to 74; Sex category (female) (CHA 2 DS 2 -VASc) score is a well validated and widely used stroke risk stratification score in patients with atrial fibrillation (AF). 5, 6 Patients with scores < 2 are considered low-stroke-risk patients, whereas those with scores ! 2 are at high risk. 6 The predictive performance of CHA 2 DS 2 -VASc score in patients undergoing SAVR so far has not been assessed. In this observational, multicenter study we sought to evaluate the performance of CHA 2 DS 2 -VASc score in predicting stroke, TIA, and major bleeds in patients undergoing SAVR with a bioprosthesis.
MATERIAL AND METHODS Data Collection
The Consortium of studies in the field of AF, Stroke, and Bleeding in Patients Undergoing Aortic Valve Replacement is a Finnish multicenter retrospective study (ClinicalTrials.gov identifier: NCT02626871) assessing the incidence and risks of AF, thromboembolic complications, and bleeding events in patients undergoing isolated bioprosthetic SAVR. The data were collected as a part of a broader ongoing consortium in Finland to evaluate the risk of thromboembolic and bleeding complications of AF in patients undergoing different cardiac procedures. 4, 7, 8 Patient data were retrieved from cardiac surgery units at 4 Finnish university hospitals (in Helsinki, Turku, Oulu, and Kuopio) over the period from 2002 to 2014 (in Helsinki 2006-2014). Hospital records were reviewed for patients who underwent isolated surgical bioprosthetic SAVR. Patients undergoing any concomitant surgery such as coronary artery bypass grafting, maze procedure with or without left atrial appendage occlusion, cryoablation, or any procedure on the ascending aorta or other heart valves were excluded from the study. Implanted valves included St Jude Medical (St Paul, Minn) Epic, Epic Supra, Biocor, and Trifecta; Medtronic (Minneapolis, Minn) Hancock II, Mosaic, and Mosaic Ultra; Carpentier Edwards (Edwards Lifesciences, Irvine, Calif) Perimount, Magna, and Magna Ease; as well as Sorin Biomedica Spa (Saluggio, Italy) Mitroflow, Soprano, Freedom solo, and Perceval. To obtain accurate follow-up data, only patients from the hospitals' catchment areas were included in this registry. All major adverse events such as cerebrovascular and bleeding events and myocardial infarctions were treated at the same hospitals, and therefore, patient follow-up for adverse events can be considered complete and reliable. Patient records were individually reviewed with a standardized structured data collection protocol for pre-and perioperative data, discharge data, and long-term follow-up events, including postoperative AF, stroke, TIA, bleeding events, and mortality.
The end points included the first occurrence of stroke or TIA or major bleeding event. Fatal strokes and bleeds were identified from Statistics Finland. This governmental office monitors the time and causes of death in Finland.
An ischemic stroke was defined as a permanent focal neurologic deficit adjudicated by a neurologist and confirmed with computed tomography or magnetic resonance imaging. TIA was defined as a transient (<24 hours) focal neurologic deficit. If a stroke or TIA was clinically diagnosed during the index hospitalization by the treating physician and confirmed by computed tomography or magnetic resonance imaging, a separate adjudication by a neurologist was not required. Only ischemic strokes and TIAs considered definite by the treating neurologist or physician were included. Subtypes of ischemic strokes were categorized by the treating physicians using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification system. 9 Lacunar stroke was defined as an infarct < 20 mm in diameter. Bleeding events were defined according to the Bleeding Academic Research Criteria (BARC). 10 BARC 3a, 3b, 3c, and 5 bleeds were considered as major bleeding events, whilst bleeding occurring immediately after the index SAVR at the hospital (BARC 4) were not considered for this analysis.
The patients were divided into 3 risk groups according to the CHA 2 DS 2 -VASc score that were calculated before index surgery: low (scores, 0-1), high (scores, 2-4), and very high (scores, 5-9). 5 Use of very high risk score category was based on the annual > 5% rate of thromboembolisms in the validation study. 6 Diabetes, dyslipidemia, and hypertension were defined as a disease requiring drug therapy and chronic lung disease as a pulmonary disease requiring a long-term use of bronchodilators or steroids. Peripheral arterial disease was defined as 1 or more of the following: claudication, carotid artery disease > 50% diameter, and previous or planned intervention of the abdominal aorta, limb arteries, or carotids. Heavy alcohol consumption was defined as > 14 doses a week for women and > 21 doses a week for men. Poor mobility was defined as severe impairment of mobility secondary to musculoskeletal or neurologic dysfunction. Urgent operation was defined as an operation scheduled during the same in-hospital stay, emergency operation as an operation before the next working day, and salvage procedure as an operation where patients require cardiopulmonary Scanning this QR code will take you to a supplemental video for this article.
The Journal of Thoracic and Cardiovascular Surgery c Volume 157, Number 3resuscitation en route to the operating theatre or before the induction of anesthesia. During the study period, the routine anticoagulation practice was 40 mg enoxaparin given subcutaneously once daily starting in the evening of the day of the surgery and continuing until vitamin K antagonist treatment (started on the first postoperative day) reached the therapeutic level (international normalized ratio ! 2.0). All patients were on vitamin K antagonist treatment a minimum duration of 3 months after index surgery. Continuation of oral anticoagulation beyond 3 months was at the treating physician's discretion.
An independent, certified third-party data monitor controlled the integrity of the data at each study site.
The study protocol was approved by the Medical Ethics Committee of the Hospital District of Southwest Finland and the ethics committee of the National Institute for Health and Welfare (Finland). Because of the retrospective, observational nature of the study, an informed consent was not required. The study conforms to the Declaration of Helsinki.
Statistical Analysis
Statistical analyses were conducted with SPSS version 24.0 (IBM-SPSS Inc, Armonk, NY) and competing risks analysis with Stata version 14.2 (StataCorp, College Station, Tex) statistical software. Continuous variables were reported as mean with standard deviation if normally distributed, and as median with interquartile range if skewed. Data were tested for normal distribution using Kolmogorov-Smirnov and Shapiro-Wilk tests. Categorical variables were described as counts and percentages. Pearson c 2 , Fisher exact test, and 1-way analysis of variance with Bonferroni correction were used for univariable analysis. Incidences of stroke/TIA and major bleeds are presented as crude cumulative Kaplan-Meier estimates. Incidence rate were calculated as number of events divided by the sum of person time at risk (events/100 patient years). Competing risk analysis was performed to account for death as a competing risk for stroke or TIA. Competing risk analysis was used to estimate the impact of CHA 2 DS 2 -VASc score on neurologic events. A competing risk is present when patients are at risk of more than one mutually exclusive event. This means that patient may die any time after surgery and this event competes with neurologic events because death prevents stroke/TIA from occurring. Herein, competing risk analysis allowed us to estimate the risk of neurologic event adjusted for the occurrence of death. Competing risk analysis was based on Fine and Gray's proportional subhazards model. 11 
RESULTS
A total of 721 patients underwent isolated bioprosthetic SAVR at the 4 participating hospitals during the study period. The median follow-up time was 4.9 (3.0-7.0) years. The final study population consisted of 714 patients as summarized in the CONSORT flow chart (Figure 1 and Online Data Supplement).
The mean preoperative CHA 2 DS 2 -VASc scores were 4.1 AE 1.6. Low (score, 0-1), high (score, 2-4), and very high (score, 5-9) scores were detected in 39 (5.5%), 400 (56.0%), and 275 (38.5%) patients, respectively. Baseline characteristics are presented in Table 1 and rhythm status and medication in Table 2 . Patients with high scores had significantly more traditional risk factors for stroke such as advanced age, prior stroke, congestive heart failure, treatment for hypertension, diabetes, and larger left atrium diameter. These patients also had a higher AF burden preoperatively, at discharge, and at 3 to 12 months postoperatively.
Strokes and TIAs
The Kaplan-Meier cumulative incidences of any stroke or TIA at 1 year were 2.6%, 4.8%, and 10.7%; at 5 years incidences were 5.2%, 14.0%, and 21.9%; and at 10 years incidences were 5.2%, 20.7%, and 37.9% for patients in low, high, and very high scores, respectively. Altogether 6 out of 38 patients (15.8%) with a TIA experienced a stroke later in life. The Kaplan-Meier cumulative incidences of cardioembolic strokes at 1 year were 0%, 1.5%, and 2.6%; at 5 years incidences were 0%, 4.0%, and 7.8%; and at 10 years incidences were 5.3%, 7.4%, and 13.9% in patients with low, high, and very high scores, respectively. Table 3 summarizes rates of stroke, TIA, stroke/TIA, and mortality per 100 patient years according to CHA 2 DS 2 -VASc scores.
Competing risk analysis showed that patients with very high risk (CHA 2 DS 2 -VASc scores, 5-9) had significantly increased risk of stroke or TIA (hazard ratio, 4.41 95% confidence interval, 1.10-17.6; P ¼ .036) compared with the low-risk group, whereas patients with high risk (CHA 2 DS 2 -VASc scores, 2-4) had nonsignificantly increased risk of stroke or TIA (hazard ratio, 2.49; 95% confidence interval, 0.62-9.98; P ¼ .198). The predictive performance of CHA 2 DS 2 -VASc in competing risk analysis remained significant for CHA 2 DS 2 -VASc scores between 5 and 9 when adjusted for preoperative AF and new-onset in-hospital AF (Table 4 ). Figure 2 depicts competing risk incidence rates of first stroke or TIA according to CHA 2 DS 2 -VASc scores classes derived from competing risks analysis. Results remained similar in a sensitivity analysis excluding patients who died in-hospital (data not shown).
At 12-month follow-up, 14.3% versus 44.3% versus 61.7% of patients were receiving oral anticoagulation 
Major Bleeds
The Kaplan-Meier cumulative incidences of major bleeds at 1 year were 0%, 1.9%, and 2.4%; at 5 years incidences were 0%, 5.4%, and 8.5%; and at 10 years incidences were 0%, 9.1%, and 27.1% in patients in low, high, and very high scores, respectively.
Because there were no major bleeds in the low risk group during the follow-up, the competing risk analysis included only patients with very high versus high risk (CHA 2 DS 2 -VASc scores 5-9). Competing risk analysis showed that very high CHA 2 DS 2 -VASc score (ie, 5-9) compared with high score was associated with increased the risk of major bleeds (HR, 1.92; 95% CI, 1.06-3.4; P ¼ .032). At the time of major bleeding event, 61.7% of patients were receiving warfarin therapy, 2.3% were receiving a nonvitamin K antagonist, 14.0% were receiving lowmolecular-weight heparin, 23.3% were taking aspirin, and 2.4% were taking P2Y12 receptor blocker medication.
DISCUSSION
CHA 2 DS 2 -VASc appears to be a simple tool to identify patients at high risk of stroke or TIA after isolated SAVR with a bioprosthesis. More than one-third of all patients undergoing SAVR were classified to be at very high estimated stroke risk (CHA 2 DS 2 -VASC score ! 5) and every fifth of these high-risk patients experienced a stroke or TIA within 5 years from index surgery indicating heavy burden of cerebrovascular events.
The present study showed that the risk of late stroke or TIA in these patients is significant and there is a need of measures for valid stratification of the risk of stroke in these patients. In patients with prior cardiac surgery, the etiology of strokes is cardioembolic in almost half of patients when assessed using TOAST criteria. 4 In fact, in our study the proportion of cardioembolic etiology of all strokes was much higher than reported in the general stroke population. 12 The rate of cardioembolic strokes also increased with increasing CHA 2 DS 2 -VASc scores. In patients with very-high-risk (CHA 2 DS 2 -VASc score ! 5) cardiogenic embolism occurred almost twice as often as in high-risk patients (CHA 2 DS 2 -VASc score 2-4) and the difference was evident already within the first year after the surgery.
The herein observed high incidence of strokes suggests that some patients with bioprosthetic SAVR may need permanent anticoagulation therapy to prevent AF-related strokes as well as emboli arising from the leaflets of the bioprosthesis. 13 Preventive strategies should be targeted in patients at high and very high risk for stroke. Obviously, cardioembolism may originate from the left atrial appendage in case of AF, from the left atrium, heart valves, left ventricle, or ascending aorta. Preventive measures include use of anticoagulant or antiplatelet medications, and occlusion of the left atrial appendage. Currently, European Society of Cardiology management guidelines for patients with AF recommend use of anticoagulation in AF patients with CHA 2 DS 2 -VASc scores ! 2 for males and ! 3 for females. 5 In addition, with CHA 2 DS 2 -VASc scores of 1 for males and 2 for females, the use of anticoagulant therapy should be considered. 5 In contrast, the use of anticoagulants without AF is far less straightforward. The European Association for CardioThoracic Surgery guidelines suggest that vitamin K antagonist treatment may be considered for 3 months after SAVR with a bioprosthesis (IIb indication, level of evidence C), but no large-scale trials have addressed this issue. 13 Nevertheless, in an observational study, the use of anticoagulation was not associated with decreased risk of strokes. 15 Preoperative permanent AF or new-onset in-hospital AF were not associated with a higher risk of stroke or TIA. This is likely explained by the more frequent use of anticoagulation therapy after surgery in patients with AF. Overall, fewer than half of patients were receiving anticoagulation therapy at the time of event. Among patients not receiving oral anticoagulation, silent AF may account for a great share of the events. 16 Among those receiving oral anticoagulation, poor anticoagulation control or stroke of atherosclerotic origin may partly account for such events.
14
Concomitant surgical closure of the left atrial appendage during the index surgery is also an option to be tested in randomized clinical trials. The efficacy of the left atrial appendage closure in these patients is currently under investigation in the Left Atrial Appendage Closure for the Prevention of Thromboembolisms in Patients Undergoing Aortic Bioprosthesis Surgery (LAA-CLOSURE) trial (ClinicalTrials.gov ID: NCT02321137) testing whether prophylactic surgical closure of the left atrial appendage decreases strokes and cardiovascular mortality in patients undergoing bioprosthetic SAVR. Indeed, the present study confirmed that major bleeding events are not infrequent complications occurring late after bioprosthetic SAVR and are mostly related to the use of antithrombotic medication. In addition, the risk of bleeding was high among patients with CHA 2 DS 2 -VASc score ! 2. Therefore, we speculate that patients at high risk of late stroke might benefit from the closure of the left atrial appendage at the time of primary surgery, avoiding the risk of stroke and TIA as well as the potential risks associated with prolonged anticoagulation.
These results should be interpreted in the light of some limitations. First, the retrospective nature is the main limitation of this study. Nevertheless, data were derived from electronic patient records and data on baseline, operative, and outcomes are routinely recorded in details at each of the participating hospitals. A validated, structured case report form was used at all study sites. As a quality control, a professional third party monitored the data. The patient population was from regional catchment areas where cerebrovascular events were treated exclusively at the participating centers. Second, the diagnosis of neurologic events was made by the treating physicians, which might have affected the sensitivity of registered end points. Nonetheless, as a result of the retrospective nature and physicians' diagnoses, there is a risk with false-negative cerebrovascular events rather than false positives. The decision regarding the use of imaging methods in the etiologic assessment of stroke or TIA was at discretion of the treating neurologist. However, especially in the case of cardioembolic stroke, the categorization is always an educated guess made by the treating physician instead of an absolute medical finding. In practice, this means that the treating neurologists used the imaging methods needed (eg, computed tomography, carotid ultrasound imaging, and echocardiogram) to exclude large artery atherosclerosis, small vessel occlusion, and other determined etiologies of stroke and to evaluate the probability of cardioembolic etiology. Based on these findings, the treating neurologists classified the neurologic events as being of cardioembolic or other etiologies. Neurologic events were defined as unknown TOAST when not otherwise categorized by the treating neurologists. Finally, the small sample size of this study is another limitation of this analysis, and therefore these findings should be viewed as hypothesis-generating.
CONCLUSIONS
More than one-third of patients undergoing SAVR are at very high of stroke or TIA as defined by CHA 2 DS 2 -VASc score ! 5 (Video 1). CHA 2 DS 2 -VASc is a valuable tool to identify patients with increased risk of stroke and major bleeding, and for whom alternative strategies for prevention of late neurologic complications should be considered.
